Marshall Wace, LLP Intellia Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 95,339 shares of NTLA stock, worth $900,953. This represents 0.0% of its overall portfolio holdings.
Number of Shares
95,339Holding current value
$900,953% of portfolio
0.0%Shares
10 transactions
Others Institutions Holding NTLA
# of Institutions
336Shares Held
96.1MCall Options Held
1.06MPut Options Held
863K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.5MShares$118 Million1.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$96.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$90.7 Million0.0% of portfolio
-
State Street Corp Boston, MA5.21MShares$49.2 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.81MShares$36 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $718M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...